Form 4: Kiora Pharmaceuticals Director Aron Shapiro Acquires Stock Options

Director Aron Shapiro acquired stock options in Kiora Pharmaceuticals through the company's 2024 Equity Incentive Plan.

Summary

• Aron Shapiro, a director of Kiora Pharmaceuticals, acquired 1,778 stock options on July 1, 2024.
• The options were granted under the Issuer's 2024 Equity Incentive Plan.
• The exercise price of the options is $4.35.
• The options will become fully exercisable on July 1, 2025, and expire on July 1, 2034.
• Following the transaction, Shapiro directly owns 1,778 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of options could be seen as a slightly positive sign, indicating the company is incentivizing its directors.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The granting of stock options to a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, Kiora Pharmaceuticals, director, Aron Shapiro, equity incentive plan, Form 4, beneficial ownership